Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 41Lymphoid 10Gastrointestinal 8Other hematologic neoplasm 6Thoracic 5Gynecologic 5Tumor-Agnostic 3Sarcoma 3Other solid neoplasm 3Head & Neck 3Genitourinary 3Plasma cell 2Dermatologic 2CNS 2Other neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasms 2Melanoma 2Pancreatic Neoplasms 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × palbociclib × Dermatologic × Clear all
NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
45 enrolled
DermatologicGastrointestinal

Melanoma, Neoplasms, Pancreatic Neoplasms

NCT02065063 2018-06-01

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
28 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡